Condition: Cord Blood Transplantation · Hematological Malignancies · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Despite anti-thymocyte globulin has a mainstay role in preventing GvHD (and non-relapse mortality) in CB transplantation, it also induces delayed immune recovery, increased risk of cytomegalovirus and Epstein-Barr virus reactivation, post-transplant lymphoproliferative diseases, overall accounting for increased transplant-related mortality and/or increased relapse incidence. All these findings support the use of alternative approaches for in vivo T cell depletion in the setting of CB transplantation.
This description comes directly from the study's public registry record.
Andrea Bacigalupo, Prof. · 0630154180 · andrea.bacigalupo@unicatt.it
Patrizia Chiusolo, MD · 0630156244 · patrizia.chiusolo@unicatt.it
Always discuss trial participation with your own doctor first.
| Fondazione Policlinico Universitario A. Gemelli IRCCS | Roma, RM, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03802773